[Summary] R&D and production of POCT in vitro diagnostic instruments and reagent
Founded in April 2008 with a registered capital of 100 million yuan, Bota Bio-Technology is committed to research on POCT precision diagnostic technologies. Its main products include various in vitro rapid diagnostic reagents and instruments for diseases based on technologies such as fluorescence immunoassay, colloidal gold, chemiluminescence, electrochemistry, high-performance liquid chromatography, molecular POCT, and dry chemistry. The company has obtained over 100 national medical device registration certificates for disease detection products covering maternal and child health, cardiovascular and cerebrovascular diseases, inflammation, tumors, respiratory tract, sex hormones, thyroid function, and chronic disease management, and has been granted more than 140 core patents (of which invention patents account for 50%). Since its establishment, the company has maintained sustained rapid growth in performance. In 2017, it transitioned from a below-scale enterprise to an above-scale enterprise. In 2018, it was rated among the top 20 comprehensive-strength POCT enterprises in China. In 2020, amid the global COVID-19 pandemic, adhering to the corporate mission of serving life and health through technological innovation, the company rapidly developed multiple COVID-19 rapid test kits, selling over 1.6 billion tests globally and achieving sales revenue exceeding 20 billion yuan. The company has successively earned dozens of honors and qualifications, including National High-Tech Enterprise, National Specialized, Refined, Distinctive, and Innovative "Little Giant" Enterprise, Fujian Province Manufacturing Leading Enterprise, Fujian Province Excellent Private Enterprise, and Xiamen City Major Taxpayer. In the lists of "2021 Fujian Top 100 Private Enterprises," "2021 Fujian Top 100 Innovative Private Enterprises," and "2021 Fujian Top 50 Manufacturing Private Enterprises," the company was the only pharmaceutical manufacturing enterprise to be included in all lists, ranking 86th, 46th, and 36th, respectively. Simultaneously, it ranked 434th in the 2022 China Top 500 Manufacturing Private Enterprises, 29th in the 2022 Fujian Top 100 Private Enterprises, 17th in the 2022 Fujian Top 50 Manufacturing Private Enterprises, and 77th in the 2023 Fujian Top 100 Manufacturing Private Enterprises.
What does Xiamen Bota Bio-Technology Joint-stock Co., Ltd. require? Who is Bota Bio-Technology hiring? Bota Bio-Technology recruitment: 销售类占比最多占39.4%，其次是工厂生产类占17.2%. What education can get in at Bota Bio-Technology? 本科占比最多占46.5%，其次是大专占45.5%. High education required at Bota Bio-Technology? 硕士占4%，博士占1%. Work experience required at Bota Bio-Technology? 3-5年占比最多占45.5%，其次是5-10年占22.2%. Where are the job locations at Bota Bio-Technology? 厦门占比最多占63.6%，其次是杭州占15.2%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
